Human volunteer studies - Safety considerations in an era of highly active biological agents: Lessons from the TeGenero tragedy

International Journal of Pharmaceutical Medicine

Volumn 20, Issue 5, 2006, Pages 293-296

  Snell, Noel J C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CHLORPHENIRAMINE; FLUPENTIXOL; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; METARAMINOL; METHIONINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TGN 1412; ONDANSETRON; PARACETAMOL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

APHASIA; BODY TEMPERATURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SAFETY; GENE THERAPY; HEADACHE; HUMAN; HYPERALGESIA; HYPOTENSION; KIDNEY DYSFUNCTION; LABORATORY TEST; MENTAL CONCENTRATION; MORTALITY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; NOTE; OXYGEN THERAPY; PARESTHESIA; PERIPHERAL ISCHEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RIGOR; RISK ASSESSMENT; SIDE EFFECT; SKIN NECROSIS; TACHYCARDIA; THORAX RADIOGRAPHY; VASODILATATION; VOLUNTEER; VOMITING;

EID: 33845367296     PISSN: 13649027     EISSN: 13649027     Source Type: Journal    
DOI: 10.2165/00124363-200620050-00002     Document Type: Note

References (30)

1. Stein C. Managing risk in healthy subjects participating in clinical research. Clin Pharmacol Ther 2003; 74: 511-2
2. Darragh A, Kenny M, Lambe R, et al. Sudden death of a volunteer. Lancet 1985; I: 93-4
3. Kolata G. The death of a research subject. Hastings Cent Rep 1980; 10 (4): 5-6
4. Trigg C, Freestone D, Lee T, et al. Death of a healthy student volunteer in a US research study: lessons for bronchoscopic practice. Int J Pharm Med 1998; 12: 151-3
5. Snell N. Death of a healthy research subject after an inhalation study: old lessons to be re-learned. Int J Pharm Med 2001; 15: 167-8
6. Cottington E, LaMantia C, Stabler S, et al. Adverse event associated with methionine loading test. Arterioscer Thromb Vasc Biol 2002; 22: 1046-50
7. Raper S, Chirmule N, Lee F, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58
8. Cardon P, Dommer F, Trumble R. Injuries to research subjects. N Engl J Med 1976; 295: 650-4
9. Zarafonetis C, Riley P, Willis P, et al. Clinically significant adverse effects in a phase I testing program. Clin Pharmacol Ther 1978; 21: 127-32
10. Royle J, Snell E. Medical research on normal volunteers. Br J Clin Pharmacol 1986; 21: 548-9
11. Williams R. First time in man studies: an academic perspective. J Clin Pharmacol 1990; 30: 210-2
12. Suntharalingam G, Perry M, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-28
13. Beyersdorf N, Hanke T, Kerkau T, et al. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis 2005; 64 Suppl. 4: iv91-5
14. Deer B. Elephant man given drug 'too quickly'. Sunday Times 2006 Sep 24 [online]. Available from URL: http:\www.timesonline.co.uk/article/0,2087- 2372235.html [Accessed 2006 Oct 5]
15. Bhattacharya S, Coghlan A. One drug, six men, disaster. New Sci 2006; 189 (2544): 10-1
16. Ghosh P. Doubt cast over drug trial safety [online]. Available from URL: http://news.bbc.co.uk/1/hi/health/4989810.stm [Accessed 2006 Oct 5]
17. Mayor S. Severe adverse reactions prompt call for trial design changes. BMJ 2006; 332: 683
18. Sheridan C. TeGenero fiasco prompts regulatory rethink. Nat Biotech 2006; 24: 475-6
19. Phan G, Haworth L, Duray P, et al. Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression [abstract 3424]. Proc Am Soc Clin Oncol 2003; 22
20. Schneider C, Kalinke U, Lower J. TGN1412: a regulator's perspective. Nat Biotech 2006; 24: 493-6
21. Investigations into adverse incidents during clinical trials of TGN1412 [online]. Available from URL: http://www.mhra.gov.uk/home/idcplg?.IdcService= SS_GET_PAGE&useSecondary=true&ssDocName=CON2023822&ssTargetNodeId= 389 [Accessed 2006 Oct 5]
22. The Academy of Medical Sciences. Testing antibody therapies: position paper [online]. Available from URL: http://www.acmedsci.ac.uk [Accessed 2006 Oct 5]
23. Bhogal N, Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. ATLA 2006; 34: 225-39
24. Expert Scientific Group on Phase One Clinical Trials: a consultation. Interim report: 20th July 2006 [online]. Available from URL: http://www.dh.gov.uk/Consultations/ClosedConsultations/ ClosedConsultationsArticle/fs/en?.CONTENT_ID=4139038&chk=Heo5Fe [Accessed 2006 Oct 5]
25. Early Stage Clinical Trial Taskforce: Joint ABPI/BIA report. Final Draft 3-7-06 [online]. Available from URL: http://www.iir-events.com/IIR-conf/PTI/ DocumentView.aspx?.EventID=199&DocumentID=504 [Accessed 2006 Oct 5]
26. National Patient Safety Agency: Central Office for Research Ethics Committees. Letter to Chairs of all NHS Research Ethics Committees in the UK. Dated 2006 Apr 28
27. Warrington S. Clinical pharmacology in the headlines: reflections on the TGN1412 trial. pA2 (Newsletter of the British Pharmacological Society) 2006; 4 (2): 8-9
28. Zammit F. Letter. New Sci 2006; 191 (2565): 21
29. Levy O, Suter E, Miller R, et al. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006; 108: 1284-90
30. Geddes L. What does the future hold for drug trial victims? New Sci 2006; 191 (2564): 10